// App-Quantinova.ai

AB0390 (2017) : EFFICACY AND SAFETY OF YISAIPU, A RECOMBINANT HUMAN TUMOR NECROSIS FACTOR-α RECEPTOR II IGG FC FUSION PROTEIN IN CHINESE PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS

Researchers

Presenter

  • R. Wu

Principal Investigators

  • N/A

Medical Centers

  • Department of Oncology, the Second Affiliated Hospital of Nanchang University, Nanchang, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxychloroquine

  • Methotrexate

  • FA-8

  • Prednisone

  • Etanercept biosimilar

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved